The method of choice was the evaluation of COMP expression by immunohistochemical staining of patients biopsies for prostate cancer and colon cancer; in the case of hepatocellular carcinoma an ELISA was used that is not IVD approved (18). The gene discussed is COMP; the disease is colonic neoplasm.